Abstract
The blockbuster model now delivers just 5% return on investment and only one in six new drug
prospects will deliver returns above their cost of capital, as a result competitive pressures and
falling R&D productivity will instigate a new pharmaceutical model that replaces the
unsustainable blockbuster model; personalized medicine and the "nichebuster". This report,
Beyond the Blockbuster Drug: Strategies for nichebuster drugs, targeted therapies and personalized
medicine, examines targeted therapies and targeted drug delivery strategies as alternative
investment options for pharmaceutical companies, in the face of declining returns and slow growth in
the blockbuster market. This reports strategic insight is also supported by in-depth interviews
with thought leaders from the pharmaceutical industry, providing you with their insight into how
tomorrows pharmaceutical business model will develop. This report analyzes the niche pharmaceutical
sectors with the greatest potential for profit and future growth. Harness the technological advances
in personalized medicine and be part of the "nichebuster" revolution set to drive market
growth and produce the market leading drugs of tomorrow. | 
View Cart
